课题基金 / 基金详情

SECOND AND THIRD-GENERATION HEPATITIS B VACCINES

SECOND AND THIRD-GENERATION HEPATITIS B VACCINES
第二代和第三代乙型肝炎疫苗
批准号：
3822063
负责人：
R H PURCELL
金额：
$0.0万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3822063
关键词：
AIDS antiviral antibody communicable disease control duck hepatitis B virus eukaryote genetic manipulation hepatitis B antigens hepatitis B virus group immunological substance live vaccine synthetic peptide synthetic vaccines vaccinia virus virus DNA

项目摘要

项目成果

R H PURCELL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Expense, availability and/or incomplete acceptance based upon an unfounded fear of infection with the agents of AIDS limit the impact of plasma-derived hepatitis B vaccines in developed and developing countries. There is therefore, a need for new approaches to vaccine development. Recombinant DNA technologies appear to offer the best opportunities for the next generation of hepatitis B vaccines. Partial or complete protection against hepatitis B has been demonstrated in chimpanzees following vaccination with (a) recombinant derived subunit vaccine prepared in eukaryotic cells, (b) live recombinant vaccinia virus containing HBV genes, and (c) synthetic peptides representing HBsAg sequences. Attempts to identify the antigenic domains most important in stimulating neutralizing antibody are currently in progress.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDIES OF ACQUIRED IMMUNE DEFICIENCY SYNDROME
SECOND AND THIRD-GENERATION HEPATITIS B VACCINES
WOODCHUCK HEPATITIS VIRUS
SECOND AND THIRD-GENERATION HEPATITIS B VACCINES
海外基金